SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : wla(warner lambert)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Anthony Wong who wrote (330)9/3/1998 8:49:00 AM
From: Henry Niman   of 942
 
The Ron Evan's paper in the Sept issue of Nature-Medicine (still
not on-line but reports linked to Rezulin table at home.att.net
) raises some questions about Rezulin and colon cancer.

Using a mouse model, a high fat diet coupled with Rezulin led to a three fold increase on
polyp formation. The relationship between TZDs like Rezulin and Avandia and cancers
like colon and breast are not clear. However, LGND has an active TZD/PPAR program,
and the above results could attract the interest of companies heavily dependent on TZD
products, like WLA.

Moreover, the FDA rejection of WLA's anti-prostate cancer drug could increase interest
in LGND's androgen program, including their anti-androgen, LGD1331.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News